Sílvia Vilarinho1,2, Sinan Sari3, Güldal Yilmaz4, Amy L Stiegler5, Titus J Boggon5,6, Dhanpat Jain1,2,7, Gulen Akyol4, Buket Dalgic3, Murat Günel2,8,9, Richard P Lifton2,9,10. 1. Department of Internal Medicine, Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT. 2. Department of Genetics, Yale University School of Medicine, New Haven, CT. 3. Department of Pediatrics, Division of Gastroenterology, Gazi University, Faculty of Medicine, Ankara, Turkey. 4. Department of Pathology, Gazi University, Faculty of Medicine, Ankara, Turkey. 5. Department of Pharmacology, Yale University School of Medicine, New Haven, CT. 6. Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, CT. 7. Department of Pathology, Yale University School of Medicine, New Haven, CT. 8. Department of Neurosurgery, Yale Program in Brain Tumor Research, Yale University School of Medicine, New Haven, CT. 9. Yale Center for Mendelian Genomics, Yale University School of Medicine, New Haven, CT. 10. Department of Internal Medicine and Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, CT.
Abstract
UNLABELLED: Despite advances in the diagnosis and management of idiopathic noncirrhotic portal hypertension, its pathogenesis remains elusive. Insight may be gained from study of early-onset familial idiopathic noncirrhotic portal hypertension, in which Mendelian mutations may account for disease. We performed exome sequencing of eight subjects from six kindreds with onset of portal hypertension of indeterminate etiology during infancy or childhood. Three subjects from two consanguineous families shared the identical rare homozygous p.N46S mutation in DGUOK, a deoxyguanosine kinase required for mitochondrial DNA replication; haplotype sharing demonstrated that the mutation in the two families was inherited from a remote common ancestor. All three affected subjects had stable portal hypertension with noncirrhotic liver disease for 6-16 years of follow-up. This mutation impairs adenosine triphosphate binding and reduces catalytic activity. Loss-of-function mutations in DGUOK have previously been implicated in cirrhosis and liver failure but not in isolated portal hypertension. Interestingly, treatment of patients with human immunodeficiency viral infection with the nucleoside analogue didanosine is known to cause portal hypertension in a subset of patients and lowers deoxyguanosine kinase levels in vitro; the current findings implicate these effects on deoxyguanosine kinase in the causal mechanism. CONCLUSION: Our findings provide new insight into the mechanisms mediating inherited and acquired noncirrhotic portal hypertension, expand the phenotypic spectrum of DGUOK deficiency, and provide a new genetic test for a specific cause of idiopathic noncirrhotic portal hypertension. (Hepatology 2016;63:1977-1986).
UNLABELLED: Despite advances in the diagnosis and management of idiopathic noncirrhotic portal hypertension, its pathogenesis remains elusive. Insight may be gained from study of early-onset familial idiopathic noncirrhotic portal hypertension, in which Mendelian mutations may account for disease. We performed exome sequencing of eight subjects from six kindreds with onset of portal hypertension of indeterminate etiology during infancy or childhood. Three subjects from two consanguineous families shared the identical rare homozygous p.N46S mutation in DGUOK, a deoxyguanosine kinase required for mitochondrial DNA replication; haplotype sharing demonstrated that the mutation in the two families was inherited from a remote common ancestor. All three affected subjects had stable portal hypertension with noncirrhotic liver disease for 6-16 years of follow-up. This mutation impairs adenosine triphosphate binding and reduces catalytic activity. Loss-of-function mutations in DGUOK have previously been implicated in cirrhosis and liver failure but not in isolated portal hypertension. Interestingly, treatment of patients with humanimmunodeficiency viral infection with the nucleoside analogue didanosine is known to cause portal hypertension in a subset of patients and lowers deoxyguanosine kinase levels in vitro; the current findings implicate these effects on deoxyguanosine kinase in the causal mechanism. CONCLUSION: Our findings provide new insight into the mechanisms mediating inherited and acquired noncirrhotic portal hypertension, expand the phenotypic spectrum of DGUOK deficiency, and provide a new genetic test for a specific cause of idiopathic noncirrhotic portal hypertension. (Hepatology 2016;63:1977-1986).
Authors: Alkes L Price; Nick J Patterson; Robert M Plenge; Michael E Weinblatt; Nancy A Shadick; David Reich Journal: Nat Genet Date: 2006-07-23 Impact factor: 38.330
Authors: David P Dimmock; J Kay Dunn; Annette Feigenbaum; Anthony Rupar; Rita Horvath; Peter Freisinger; Bénédicte Mousson de Camaret; Lee-Jun Wong; Fernando Scaglia Journal: Liver Transpl Date: 2008-10 Impact factor: 5.799
Authors: Lynn M Boyden; Murim Choi; Keith A Choate; Carol J Nelson-Williams; Anita Farhi; Hakan R Toka; Irina R Tikhonova; Robert Bjornson; Shrikant M Mane; Giacomo Colussi; Marcel Lebel; Richard D Gordon; Ben A Semmekrot; Alain Poujol; Matti J Välimäki; Maria E De Ferrari; Sami A Sanjad; Michael Gutkin; Fiona E Karet; Joseph R Tucci; Jim R Stockigt; Kim M Keppler-Noreuil; Craig C Porter; Sudhir K Anand; Margo L Whiteford; Ira D Davis; Stephanie B Dewar; Alberto Bettinelli; Jeffrey J Fadrowski; Craig W Belsha; Tracy E Hunley; Raoul D Nelson; Howard Trachtman; Trevor R P Cole; Maury Pinsk; Detlef Bockenhauer; Mohan Shenoy; Priya Vaidyanathan; John W Foreman; Majid Rasoulpour; Farook Thameem; Hania Z Al-Shahrouri; Jai Radhakrishnan; Ali G Gharavi; Beatrice Goilav; Richard P Lifton Journal: Nature Date: 2012-01-22 Impact factor: 49.962
Authors: Sílvia Vilarinho; Sinan Sari; Francesca Mazzacuva; Kaya Bilgüvar; Güldal Esendagli-Yilmaz; Dhanpat Jain; Gülen Akyol; Buket Dalgiç; Murat Günel; Peter T Clayton; Richard P Lifton Journal: Proc Natl Acad Sci U S A Date: 2016-09-19 Impact factor: 11.205
Authors: Ashish Goel; V Raghupathy; G J Amirtharaj; Aaron Chapla; Aparna Venkatraman; Banumathi Ramakrishna; Anup Ramachandran; Nihal Thomas; K A Balasubramanian; Ian Mackie; Elwyn Elias; Chundamannil E Eapen Journal: Indian J Gastroenterol Date: 2017-10-05
Authors: Kaela Drzewiecki; Jungmin Choi; Joseph Brancale; Michael A Leney-Greene; Sinan Sari; Buket Dalgiç; Aysel Ünlüsoy Aksu; Gülseren Evirgen Şahin; Ahmet Ozen; Safa Baris; Elif Karakoc-Aydiner; Dhanpat Jain; David Kleiner; Michael Schmalz; Kadakkal Radhakrishnan; Junhui Zhang; Kasper Hoebe; Helen C Su; João P Pereira; Michael J Lenardo; Richard P Lifton; Sílvia Vilarinho Journal: J Exp Med Date: 2021-05-06 Impact factor: 14.307
Authors: Ashish Goel; Banumathi Ramakrishna; Uday Zachariah; K G Sajith; Deepak K Burad; Thomas A Kodiatte; Shyamkumar N Keshava; K A Balasubramanian; Elwyn Elias; C E Eapen Journal: Indian J Med Res Date: 2019-04 Impact factor: 2.375
Authors: Angela Puente; Jose Ignacio Fortea; Carmen Del Pozo; Patricia Huelin; Maria Luisa Cagigal; Marina Serrano; Joaquin Cabezas; Maria Teresa Arias Loste; Paula Iruzubieta; Antonio Cuadrado; Susana Llerena; Carlos Lopez; Emilio Fábrega; Javier Crespo Journal: Cells Date: 2019-11-24 Impact factor: 6.600